The proposed rule would allow multiple manufacturing units at different locations to register as one establishment.
This deal comes a little after Bayer broke its pharma dealmaking fast and the company looks to optimise its long-term strategy.
The decisions are based on findings from the Phase III KEYNOTE-B15 trial.
Takeda plans to invest up to $30m to begin establishing an ecosystem for PDMPs and a plasma donation pilot.
The funds will support the progression of MindRank’s pipeline, which is heavily dominated by obesity indications.
The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.
